Dataset from A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00006545
下载链接
链接失效反馈官方服务：
资源简介：
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus
tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive
(HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.
创建时间：
2025-11-14
